Search results
Results from the WOW.Com Content Network
Teriflunomide inhibits rapidly dividing cells, including activated T cells, which are thought to drive the disease process in MS. Teriflunomide may decrease the risk of infections compared to chemotherapy-like drugs because of its more-limited effects on the immune system.
Fenfluramine is indicated for the treatment of seizures associated with Dravet syndrome and Lennox–Gastaut syndrome in people age two and older. [3] [7] [4]Dravet syndrome is a life-threatening, rare and chronic form of epilepsy. [7]
Flutamide has been researched and used extensively in the treatment of androgen-dependent skin and hair conditions in women including acne, seborrhea, hirsutism, and scalp hair loss, as well as in hyperandrogenism (e.g., in polycystic ovary syndrome or congenital adrenal hyperplasia), and is effective in improving the symptoms of these conditions.
[7] [9] [10] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. [11] In January 2024, the FDA approved erdafitinib for adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test, whose disease has ...
Dutasteride was patented in 1993 by GlaxoSmithKline and was approved for medical use in 2001. [12] [8] In the United States and elsewhere, it is available as a generic medication. [5] In 2018, it was the 291st-most commonly prescribed medication in the US with more than 1 million prescriptions. [13]
The one-time therapy, branded as Lenmeldy in the U.S., is approved for children in certain stages of disease progression, the Food and Drug Administration (FDA) said. US approves first gene ...
(Reuters) -The U.S. FDA has approved Madrigal Pharmaceuticals' drug for a fatty liver disease known as non-alcoholic steatohepatitis (NASH), the first treatment to get the nod for the condition ...
Casimersen was approved for medical use in the United States in February 2021, [1] [2] [6] and it is the first FDA-approved targeted treatment for people who have a confirmed mutation of the DMD gene that is amenable to skipping exon 45. [2]